Wakix -Pitolisant Tablets

WAKIX® is a narcolepsy treatment that Citrine has in-licensed from the French biotech company, Bioprojet, for use in China. WAKIX®(Pitolisant) is the first-in-class novel mechanism H3 receptor antagonist approved by the European Medicines Agency (EMA) in 2016 and by FDA in 2018. It will be the first approved medicine for narcolepsy treatment in China. In the mean time, it has the potential to expand its indication to the treatment of pediatric narcoleptic patients with or without cataplexy and obstructive sleep apnea syndrome.